Highlights of eosinophilic chronic rhinosinusitis with nasal polypsin definition, prognosis, and advancement

REVIEW ARTICLE 

Open Access

Hongfei Lou MD, PhD 

 

Nan Zhang MD, PhD 

 

Claus Bachert MD, PhD 

 

Luo Zhang MD, PhD

https://doi.org/10.1002/alr.22214

Abstract

Background

Tissue eosinophils are characteristic of inflammation in most but not all patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and may be useful for defining subgroups and making treatment choices. However, no consistent diagnostic criteria for CRSwNP with eosinophilic inflammation have been established.

Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients

Eur Rev Med Pharmacol Sci 2018; 22 (3): 820-828

DOI: 10.26355/eurrev_201802_14318

A. Demonte, M.B. Guanti, S. Liberati, A. Biffi, F. Fernando, M. Fainello, P. Pepe

Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine; Dermatology Unit; University of Modena and Reggio Emilia, Modena, Italy. patrizia.pepe@unimore.it

---

• PHARMACOLOGY

OBJECTIVE: Bilastine is a highly selective, non-sedating antihistamine, indicated for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. Available data suggest that bilastine interferes neither with driving ability nor with flying-related performance. However, no data are available on the effect of bilastine on the driving ability in extreme conditions. Here we analyzed the effect of 7 days treatment with 20 mg bilastine in patients with allergic rhinitis and/or chronic urticaria, on psychophysical performance assessed by the Formula One (F1) high-speed simulator-driving test.

Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings

Original Investigation 

Public Health

Jenna Tucker, MPH^1,2,3; Tessa Fischer, DVM, MPH^2,3; Laurence Upjohn, PharmD³; et alDavid Mazzera, PhD³; Madhur Kumar, MS, PhD³

Author Affiliations Article Information

JAMA Network Open. 2018;1(6):e183337. doi:10.1001/jamanetworkopen.2018.3337

editorial comment i

Key Points

Question  What are the trends across adulterated dietary supplements associated with a warning released by the US Food and Drug Administration from 2007 through 2016?

Findings  In this quality improvement study, analysis of the US Food and Drug Administration warnings from 2007 through 2016 showed that unapproved pharmaceutical ingredients were identified in 776 dietary supplements, and these products were commonly marketed for sexual enhancement, weight loss, or muscle building. The most common adulterants were sildenafil for sexual enhancement supplements, sibutramine for weight loss supplements, and synthetic steroids or steroid-like ingredients for muscle building supplements, with 157 products (20.2%) containing more than 1 unapproved ingredient.

Rhinosectan® spray (containing xyloglucan) on the ciliary function of the nasal respiratory epithelium; results of an in vitro study

• Research
• Open Access

Allergy, Asthma & Clinical Immunology201814:41

https://doi.org/10.1186/s13223-018-0268-3

• Núria Piqué

and

Barbara De Servi

Abstract

Background

To assess the effects of Rhinosectan® spray, a medical device containing xyloglucan, on nasal ciliary function (in MucilAir™Nasal cells).

Practical guide for allergy and immunology in Canada 2018

Allergy, Asthma & Clinical Immunology

1. Introduction

   Introduction from the Editors

   Authors:Harold Kim, Richard Warrington and Wade Watson

   Citation:Allergy, Asthma & Clinical Immunology 2018 14(Suppl 2):48

   Published on: 12 September 2018

   • ViewFull Text
    
   • ViewPDF
2. Content Type:Review

   An introduction to immunology and immunopathology

   Beyond structural and chemical barriers to pathogens, the immune system has two fundamental lines of defense: innate immunity and adaptive immunity. Innate immunity is the first immunological mechanism for fig...

   Authors:Jean S. Marshall, Richard Warrington, Wade Watson and Harold L. Kim

   Citation:Allergy, Asthma & Clinical Immunology 2018 14(Suppl 2):49

   Published on: 12 September 2018

   • ViewFull Text
    
   • ViewPDF

Kimishige Ishizaka (1925–2018)

Hirohisa SaitoEmail the author Hirohisa Saito

National Research Institute for Child Health & Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan

Open Access

DOI: https://doi.org/10.1016/j.alit.2018.07.007

Article Info

• Abstract

• Full Text

• Images
• References

Article Outline

1. Conflict of interest
2. References

Dr. Kimishige Ishizaka (Fig. 1) passed peacefully away from heart failure at dawn of July 6, 2018 in Yamagata, Japan. Dr. Kimishige Ishizaka and Dr. Teruko Ishizaka (the Ishizakas; partners in marriage and in research) were best known for their discovery of immunoglobulin E (IgE) in 1966.1

Fig. 1

Kimishige Ishizaka, December 3, 1925–July 6, 2018. A photo was taken at the reception celebrating the 50th Anniversary of IgE Discovery held at the 65th Annual Meeting of Japanese Society of Allergology, on June 19, 2016.

The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation

• Review
• Open Access

• Christian Domingo,
• Oscar Palomares,
• David A. Sandham,
• Veit J. Erpenbeck and
• Pablo AltmanEmail author

Respiratory Research201819:189

Abstract

Asthma is characterised by chronic airway inflammation, airway obstruction and hyper-responsiveness. The inflammatory cascade in asthma comprises a complex interplay of genetic factors, the airway epithelium, and dysregulation of the immune response.

Gut microbiota relationships to lung function and adult asthma phenotype: a pilot study

BMJ Open Respiratory Research 2018;5:e000324. doi: 10.1136/bmjresp-2018-000324

Lesa Begley1,  Siddharth Madapoosi1,  Kristopher Opron1,2,  Ogechukwu Ndum3,  Alan Baptist3,  Kelly Rysso1,  John R Erb-Downward1 and  Yvonne Jean Huang1
Abstract
Introduction Despite strong evidence that maturation patterns of the gut microbiome in early life influence the risk for childhood asthma, very little is known about gut microbiota patterns in adults with established asthma, and of greater interest relationships to phenotypic features that characterise asthma heterogeneity.